AN2 Therapeutics annual return on equity
2022
2023
2024
2025
AN2 Therapeutics Return on Equity (ROE) Growth & History (ANTX)
AN2 Therapeutics's return on equity was −52.14% for fiscal 2025.
View full AN2 Therapeutics company overviewAN2 Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −52.14% | −2.45 pp |
| 2024 | 2024-12-31 | −49.69% | +9.13 pp |
| 2023 | 2023-12-31 | −58.83% | +111.96 pp |
| 2022 | 2022-12-31 | −170.79% | — |
AN2 Therapeutics quarterly return on equity
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −10.38% | −1.29 pp |
| Q1 2026 | 2026-03-31 | −14.88% | −1.15 pp |
| Q4 2025 | 2025-12-31 | −15.36% | −6.48 pp |
| Q3 2025 | 2025-09-30 | −14.48% | −0.77 pp |
| Q2 2025 | 2025-06-30 | −9.09% | +4.73 pp |
| Q1 2025 | 2025-03-31 | −13.72% | +0.40 pp |
| Q4 2024 | 2024-12-31 | −8.87% | +3.94 pp |
| Q3 2024 | 2024-09-30 | −13.70% | +1.03 pp |
| Q2 2024 | 2024-06-30 | −13.82% | +4.75 pp |
| Q1 2024 | 2024-03-31 | −14.12% | +3.10 pp |
| Q4 2023 | 2023-12-31 | −12.82% | −1.03 pp |
| Q3 2023 | 2023-09-30 | −14.74% | −4.50 pp |
| Q2 2023 | 2023-06-30 | −18.56% | −9.81 pp |
| Q1 2023 | 2023-03-31 | −17.23% | +5.29 pp |
| Q4 2022 | 2022-12-31 | −11.79% | — |
| Q3 2022 | 2022-09-30 | −10.24% | — |
| Q2 2022 | 2022-06-30 | −8.75% | — |
| Q1 2022 | 2022-03-31 | −22.52% | — |
AN2 Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, AN2 Therapeutics's return on equity increased from −170.79% to −52.14%, a change of +118.64 percentage points. The latest reported quarter, Q2 2026, shows −10.38%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AN2 Therapeutics source filings ↗